Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
Cardiovascular Protection Conservative Effects of Esketamine Versus µ-opioid Receptor Agonists in General Anesthesia

. Transient receptor potential vanilloid 1 (TRPV1), as a nociceptor, promotes the release of calcitonin gene-related peptide (CGRP) and substance P (SP) in the small diameter primary sensory neurons

  • 0 views
  • 02 May, 2022
  • 1 location
Effect of Preoperative Oral Pregabalin Versus Intraoperative Fentanyl on Postoperative Analgesia

modulates the release of excitatory neurotransmitters, such as glutamate, norepinephrine, substance-P, and calcitonin gene related peptide. Also, it causes inhibitory modulation of overexcited neurons and

Accepts healthy volunteers
  • 0 views
  • 14 Apr, 2022
Galcanezumab for Vestibular Migraine

Vestibular migraine (VM) has been recognized a distinct subtype of migraine that causes dizziness as the predominant symptom. Criteria for diagnosis have been adopted by the Barany Society. Previous epidemiological research from the investigators has shown that VM affects 2.7% of the adult population of the United States. Yet, despite …

  • 0 views
  • 06 Apr, 2022
  • 1 location
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.

This study is a single center, placebo-controlled, double blind, randomized, phase II pilot to evaluate the efficacy of erenumab-aooe in the management of trigeminal neuropathic pain comparing erenumab-aooe vs Placebo. A total of 40 patients (20 each arm) aged 18-65 years old of either sex, and any race or ethnicity, …

  • 0 views
  • 15 May, 2022
  • 1 location
Registry for Migraine - Clinical Core

This study aims to investigate the effect of erenumab on efficacy outcomes, tolerability outcomes, and patient-reported outcomes in individuals with migraine. Furthermore, the study aims to identify clinical predictors of erenumab response.

headache
erenumab
  • 0 views
  • 26 Jan, 2021
  • 1 location
Decoding Pain Sensitivity in Migraine With Multimodal Brainstem-based Neurosignature

Migraine is a highly prevalent and disabling neurological disease, which has a tremendous impact on sufferers, healthcare systems, and the economy. According to the 2016 WHO report, migraine is the second leading cause of years lived with disability, greater than all other neurological diseases combined. Yet, the treatment in migraine …

  • 0 views
  • 24 Apr, 2021
  • 1 location
The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients

A randomized, double-blind, placebo-controlled, parallel study to investigate the effect of erenumab in calcitonin-gene related peptide and cilostazol experimental models of migraine in humans

calcitonin
erenumab
calcitonin gene-related peptide
cilostazol
headache
  • 24 views
  • 26 Jan, 2021
  • 1 location
Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab

To explore the relationship between clinical response to erenumab and response to intravenous infusion of calcitonin gene-related peptide in individuals with migraine.

calcitonin
calcitonin gene-related peptide
headache
erenumab
  • 0 views
  • 26 Jan, 2021
  • 1 location
The Effects of Levcromakalim in Patients With Cluster Headache

disease mechanisms that will ultimately lead to the development of disease-specific medicines. Until now, it has been suggested that the calcitonin gene-related peptide (CGRP) plays a major role in the

  • 0 views
  • 24 Mar, 2022
  • 1 location
Rimegepant in Moderate Plaque-type Psoriasis

administered small molecule competitive inhibitor of the calcitonin gene-related peptide (CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade name Nurtec for the treatment

  • 0 views
  • 19 Nov, 2021
  • 1 location